IVOSIDENIB

Information current as at: 1 May 2025

PBAC meeting date: July 2024
Legend: Completed N In progress Not applicable N Yet to commence

Submission Details

Brand name:
  • Tibsovo®
Pharmaceutical company:
SERVIER LABORATORIES (AUST.) PTY. LTD.
Condition/indication:
(therapeutic use)
  • Bile duct cancer (cholangiocarcinoma)
PBAC Submission type:
New PBS listing (Category 1)
Comment:
--
Related medicines:
--

Progress Details

Submission received for:
July 2024 PBAC meeting
Opportunity for consumer comment:
Open 03/04/2024 and close 29/05/2024 (see PBS Website)
PBAC meeting:
Held on 10/07/2024
PBAC outcome published:
Not Recommended (see PBAC Outcomes)
5Lodgement of required documentation:
Has not yet commenced
6Agreement to listing arrangements:
Has not yet commenced
7Government processes:
Has not yet commenced
8Medicine listed on the PBS:
Has not yet occurred

Case ID: a885

Page last updated: 23 April 2025

v.9.18